ArticleHaematologica2022

Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.

Idanna Innocenti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.